EyePoint Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
EYPT$0.40+11.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(In thousands)
| Year Ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(130,870) | $(70,795) |
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||
| Depreciation of property and equipment | 1,540 | 464 |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | (5,953) | (856) |
| Provision for excess and obsolete inventory | — | 693 |
| Loss on extinguishment of debt | — | 1,347 |
| Stock-based compensation | 36,740 | 12,057 |
| Deferred income tax | 90 | 83 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other current assets | (244) | 14,432 |
| Other assets | (5,832) | — |
| Inventory | 1,600 | (1,553) |
| Accounts payable and accrued expenses | 5,731 | 1,519 |
| Right-of-use assets and operating lease liabilities | 1,618 | (39) |
| Deferred revenue | (30,646) | 44,523 |
| Net cash (used in) provided by operating activities | (126,226) | 1,875 |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (398,303) | (55,116) |
| Sales and maturities of marketable securities | 183,000 | 55,284 |
| Purchases of property and equipment | (4,052) | (3,483) |
| Net cash (used in) provided by investing activities | (219,355) | (3,315) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of stock | 163,314 | 226,174 |
| Payment of equity issue costs | (672) | (451) |
| Payment of long-term debt | — | (30,000) |
| Payment of extinguishment of debt costs | — | (1,350) |
| Borrowings under revolving facility | — | 5,300 |
| Repayment under revolving facility | — | (15,775) |
| Net settlement of stock units to satisfy statutory tax withholding | (4,512) | (169) |
| Proceeds from exercise of stock options and employee stock purchase plan | 5,997 | 3,377 |
| Principal payments on finance lease obligations | (105) | (36) |
| Net cash provided by (used in) financing activities | 164,022 | 187,070 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (181,559) | 185,630 |
| Cash, cash equivalents and restricted cash at beginning of period | 281,413 | 95,783 |
| Cash, cash equivalents and restricted cash at end of period | $99,854 | $281,413 |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $99,704 | $281,263 |
| Restricted cash | 150 | 150 |
| Total cash, cash equivalents and restricted cash at end of period | $99,854 | $281,413 |
| Supplemental cash flow information: | ||
| Cash interest paid | — | $1,405 |
| Supplemental disclosure of non-cash investing and financing activities: | — | — |
| Lease liability arising from obtaining right-of-use assets | $17,544 | $— |
| Stock issuance costs | $311 | $325 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.